-
Hyderabad: Hyderabad-based Hetero unveiled results of phase III trials of Movfor (Molnupiravir), an investigational oral antiviral Covid-19 drug. The company demonstrated that Molnupiravir along with Standard of Care (SOC) reduced the risk of hospitalisation by over 65 per cent compared to SOC alone. The results were presented as an oral abstract at the Conference on […]
-
Hyderabad: Dr Reddy’s is strengthening its Covid portfolio with a range of drugs and vaccine options. The company is in various stages of regulatory clearances for Sputnik Light and Sputnik V booster dose. Phase III clinical trial data of Sputnik Light has been submitted to the Indian regulator. Additional data from clinical trials for Sputnik […]
-
New Delhi: The ICMR’s National Task Force for Covid-19 has decided against including antiviral drug Molnupiravir in the Clinical Management Protocol for Covid as of now, official sources said on Tuesday. The experts of the task force cited safety concerns and argued that Molnupiravir was not of much benefit in Covid treatment to arrive at […]
-
Hyderabad: Amid safety concerns around antiviral drug molnupiravir, the US-based pharma company MSD (Merck is known as MSD outside the US and Canada) came out in defence of its drug developed in collaboration with Ridgeback Biotherapeutics. The company in its statement on Friday, said, “We are confident in the clinical profile of molnupiravir, which demonstrated […]
-
Hyderabad: MSN Group, a Hyderabad-based pharma company, is all set to launch the generic molnupiravir 200 mg capsules for treating Covid-19 under the brand name Moluflow. Molnupiravir is an oral Covid-19 antiviral medicine indicated for the treatment of mild-to-moderate Covid-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk […]
-
Hyderabad: Dr Reddy’s Laboratories said on Tuesday the company will launch its molnupiravir capsules 200mg under its brand name Molflu across India. The drug will be priced at Rs 35 per capsule with 10 capsules contained per strip, and the total course of 40 capsules over five days costing Rs 1,400. Molflu is expected to […]
-
New Delhi: Covid antiviral drug Molnupiravir was on Monday launched in India at Rs 1,399 for a five-day course for mild to moderate infection. Amid rising cases of new Covid variant Omicron in the country, an expert panel of the Central Drugs Standard Control Organisation had recently approved antiviral drug Molnupiravir for restricted use in […]
-
Hyderabad: Hyderabad-based Hetero, a vertically integrated pharmaceutical organisation, has received Drug Controller General of India (DCGI) nod for manufacture and marketing of molnupiravir capsules 200 mg (Movfor). Molnupiravir is an oral antiviral indicated for restricted emergency use in India to treat adult patients with Covid-19. Hetero’s Movfor will be made available in a 40 capsule […]
-
Hyderabad: Hyderabad-based Optimus Pharma launched their frontline Covid-19 medication molnupiravir in the Indian market, as they have received permission for the restricted emergency use for Covid-19 drug. Optimus Pharma is ready with a commercial quantity of the drug. The company has completed its phase 3 clinical trials on 1,218 subjects across 29 geographical study sites […]
-
Hyderabad: The much-awaited first oral medication for Covid-19 based on Molnupiravir is expected to hit the shelves of drug stores in the coming months. While the oral pill has received lot of attention for its therapeutic promise in reducing hospital stay and death risk among Covid patients, the fact remains that Hyderabad, due to its […]
-
Hyderabad: A simple pill to treat Covid-19 positive patients! Yes, an anti-viral pill that could be easily prescribed and taken orally by Covid positive patients with a promise of cutting down the risk of hospitalisation and death by at least by half, could hit the Indian markets in the coming months. Multiple research institutions and […]
-
The interim results on 353 patients showed that the drug has been successful in reducing viral load effectively with RT-PCR negativity.
-
Hyderabad-based pharma company has approached the Drug Controller General of India to seek Emergency Use Authorization for the investigational drug in India
-
On successful completion of the clinical trial, each company will independently approach the regulatory authorities for approval to manufacture and supply the drug for the treatment of Covid-19 in India
-
The synthetic process know-how for Molnupiravir was sourced from CSIR-NIIST and scale up process was successfully carried out by CSIR-IICT
-
The clinical trials will be performed on more than 2,400 subjects suffering from mild to moderate Covid-19, across over 40 sites in India
-
Natco Pharma had recently received approval from the Drug Controller General of India (DCGI) to conduct phase III clinical trials of Molnupiravir
-
The drug regulator gave nod for conducting the trial on mild and moderate Covid-19 patients
-
Under this licensing deal, Hetero will be allowed to expand access of Molnupiravir in India and in other low-and middle-income countries (LMICs), following the approvals for emergency use authorisation.
